Literature DB >> 29291252

TFPIα interacts with FVa and FXa to inhibit prothrombinase during the initiation of coagulation.

Jeremy P Wood1, Helle H Petersen2, Bingke Yu3, Xiaoai Wu3, Ida Hilden2, Alan E Mast1,4.   

Abstract

Tissue factor pathway inhibitor α (TFPIα) inhibits prothrombinase, the thrombin-generating complex of factor Xa (FXa) and factor Va (FVa), during the initiation of coagulation. This inhibition requires binding of a conserved basic region within TFPIα to a conserved acidic region in FXa-activated and platelet-released FVa. In this study, the contribution of interactions between TFPIα and the FXa active site and FVa heavy chain to prothrombinase inhibition were examined to further define the inhibitory biochemistry. Removal of FXa active site binding by mutation or by deletion of the second Kunitz domain (K2) of TFPIα produced 17- or 34-fold weaker prothrombinase inhibition, respectively, establishing that K2 binding to the FXa active site is required for efficient inhibition. Substitution of the TFPIα basic region uncharged residues (Leu252, Ile253, Thr255) with Ala (TFPI-AAKA) produced 5.8-fold decreased inhibition. This finding was confirmed using a basic region peptide (Leu252-Lys261) and Ala substitution peptides, which established that the uncharged residues are required for prothrombinase inhibitory activity but not for binding the FVa acidic region. This suggests that the uncharged residues mediate a secondary interaction with FVa subsequent to acidic region binding. This secondary interaction seems to be with the FVa heavy chain, because the FV Leiden mutation weakened prothrombinase inhibition by TFPIα but did not alter TFPI-AAKA inhibitory activity. Thus, efficient inhibition of prothrombinase by TFPIα requires at least 3 intermolecular interactions: (1) the TFPIα basic region binds the FVa acidic region, (2) K2 binds the FXa active site, and (3) Leu252-Thr255 binds the FVa heavy chain.

Entities:  

Year:  2017        PMID: 29291252      PMCID: PMC5745139          DOI: 10.1182/bloodadvances.2017011098

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  49 in total

1.  Coagulation procofactor activation by factor XIa.

Authors:  M F Whelihan; T Orfeo; M T Gissel; K G Mann
Journal:  J Thromb Haemost       Date:  2010-05-04       Impact factor: 5.824

2.  Functional characterization of human platelet-released factor V and its activation by factor Xa and thrombin.

Authors:  D D Monković; P B Tracy
Journal:  J Biol Chem       Date:  1990-10-05       Impact factor: 5.157

Review 3.  Surface-dependent reactions of the vitamin K-dependent enzyme complexes.

Authors:  K G Mann; M E Nesheim; W R Church; P Haley; S Krishnaswamy
Journal:  Blood       Date:  1990-07-01       Impact factor: 22.113

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis.

Authors:  B Zöller; B Dahlbäck
Journal:  Lancet       Date:  1994-06-18       Impact factor: 79.321

6.  Polyphosphate exerts differential effects on blood clotting, depending on polymer size.

Authors:  Stephanie A Smith; Sharon H Choi; Rebecca Davis-Harrison; Jillian Huyck; John Boettcher; Chad M Rienstra; Chad M Reinstra; James H Morrissey
Journal:  Blood       Date:  2010-08-13       Impact factor: 22.113

7.  Characterization of the molecular defect in factor VR506Q.

Authors:  M Kalafatis; R M Bertina; M D Rand; K G Mann
Journal:  J Biol Chem       Date:  1995-02-24       Impact factor: 5.157

8.  Coagulation factor V(A2440G) causes east Texas bleeding disorder via TFPIα.

Authors:  Lisa M Vincent; Sinh Tran; Ruzica Livaja; Tracy A Bensend; Dianna M Milewicz; Björn Dahlbäck
Journal:  J Clin Invest       Date:  2013-08-27       Impact factor: 14.808

9.  Homology model of human prothrombinase based on the crystal structure of Pseutarin C.

Authors:  Anja Pomowski; Fatma Isik Ustok; James A Huntington
Journal:  Biol Chem       Date:  2014-10       Impact factor: 3.915

10.  Factor V has an anticoagulant cofactor activity that targets the early phase of coagulation.

Authors:  Salvatore Santamaria; Natalia Reglińska-Matveyev; Magdalena Gierula; Rodney M Camire; James T B Crawley; David A Lane; Josefin Ahnström
Journal:  J Biol Chem       Date:  2017-04-18       Impact factor: 5.157

View more
  15 in total

1.  A mathematical model of coagulation under flow identifies factor V as a modifier of thrombin generation in hemophilia A.

Authors:  Kathryn G Link; Michael T Stobb; Matthew G Sorrells; Maria Bortot; Katherine Ruegg; Marilyn J Manco-Johnson; Jorge A Di Paola; Suzanne S Sindi; Aaron L Fogelson; Karin Leiderman; Keith B Neeves
Journal:  J Thromb Haemost       Date:  2019-11-01       Impact factor: 5.824

2.  Factor V east Texas variant causes bleeding in a three-generation family.

Authors:  Julie A Peterson; Sweta Gupta; Nicholas D Martinez; Brandon Hardesty; Susan A Maroney; Alan E Mast
Journal:  J Thromb Haemost       Date:  2021-12-07       Impact factor: 5.824

3.  Maintaining extraembryonic expression allows generation of mice with severe tissue factor pathway inhibitor deficiency.

Authors:  Michelle M Castillo; Qiuhui Yang; Min Zhan; Amy Y Pan; Michael W Lawlor; Alan E Mast; Rashmi Sood
Journal:  Blood Adv       Date:  2019-02-12

4.  Platelet anticoagulant proteins: Modulators of thrombosis propensity within a procoagulant cell.

Authors:  Amy E Siebert; Alan E Mast
Journal:  J Thromb Haemost       Date:  2020-07-30       Impact factor: 5.824

5.  CD248 enhances tissue factor procoagulant function, promoting arterial and venous thrombosis in mouse models.

Authors:  Piyushkumar R Kapopara; Nooshin S Safikhan; Jenny L Huang; Scott C Meixner; Kevin Gonzalez; Houra Loghmani; Wolfram Ruf; Alan E Mast; Victor Lei; Edward L G Pryzdial; Edward M Conway
Journal:  J Thromb Haemost       Date:  2021-05-07       Impact factor: 16.036

6.  Major Reservoir for Heparin-Releasable TFPIα (Tissue Factor Pathway Inhibitor α) Is Extracellular Matrix.

Authors:  Julie A Peterson; Susan A Maroney; Nicholas D Martinez; Alan E Mast
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-04-08       Impact factor: 10.514

7.  Intersection of regulatory pathways controlling hemostasis and hemochorial placentation.

Authors:  Masanaga Muto; Damayanti Chakraborty; Kaela M Varberg; Ayelen Moreno-Irusta; Khursheed Iqbal; Regan L Scott; Ross P McNally; Ruhul H Choudhury; John D Aplin; Hiroaki Okae; Takahiro Arima; Shoma Matsumoto; Masatsugu Ema; Alan E Mast; Elin Grundberg; Michael J Soares
Journal:  Proc Natl Acad Sci U S A       Date:  2021-12-14       Impact factor: 12.779

8.  The contribution of TFPIα to the hemostatic response to injury in mice.

Authors:  Tanya T Marar; Nicholas D Martinez; Susan A Maroney; Amy E Siebert; Jie Wu; Timothy J Stalker; Maurizio Tomaiuolo; Sinny Delacroix; Robert D Simari; Alan E Mast; Lawrence F Brass
Journal:  J Thromb Haemost       Date:  2021-07-14       Impact factor: 16.036

9.  Intrauterine lethality in Tfpi gene disrupted mice is differentially suppressed during mid- and late-gestation by platelet TFPIα overexpression.

Authors:  Amy E Siebert; Susan A Maroney; Nicholas D Martinez; Alan E Mast
Journal:  J Thromb Haemost       Date:  2021-04-12       Impact factor: 16.036

10.  Tissue factor pathway inhibitor is required for cerebrovascular development in mice.

Authors:  Susan A Maroney; Randal J Westrick; Audrey C Cleuren; Nicholas D Martinez; Amy E Siebert; Mark Zogg; David Ginsburg; Hartmut Weiler; Alan E Mast
Journal:  Blood       Date:  2021-01-14       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.